Scope, Claims, and US Patent Landscape for US Patent 9,216,176
US Patent 9,216,176 claims an abuse-resistant oral solid built from coated granules dispersed in a hydroxypropyl methyl cellulose (HPMC) / lactose matrix, where the granule core contains an opioid (or salt) plus ethylcellulose and the granule coat contains ethylcellulose plus glyceryl behenate. The claims are anchored to quantitative composition ranges and to abuse-relevant release limits tested using USP Apparatus 2 under specified media and with a crush condition.
What is the independent claim scope?
Claim 1 (broadest composition + first abuse-release test framework)
Claim 1 covers:
A. Tablet structure
- Plurality of coated granules
- Each coated granule has:
- (i) Uncoated granule (core) composition
- Opioid and/or salt: 20 to 60% by weight of the uncoated granule
- Ethylcellulose: 10 to 75%
- HPMC: 15 to 50%
- (ii) Coating surrounding the granule
- Ethylcellulose (in coating): 20 to 60% by weight of coated granule
- Glyceryl behenate (in coating): 10 to 30%
- Tablet contains coated granules in an amount to deliver a therapeutically effective opioid dose
- Matrix composition:
- HPMC: 2 to 20% by weight of the tablet
- Lactose: 10 to 75% by weight of the tablet
B. Key abuse resistance limitation (not an independent numeric screen in claim 1, but sets the claim family’s test logic)
- Claim 1 itself is structural and composition-based. The abuse-release numeric thresholds appear in dependent claims.
Claim 6 and claim 8 (second and third abuse-release frameworks)
These dependent-to-independent style claims add more explicit release-limit requirements.
Claim 6 (two-hour release in ethanol media + crush/0.1N HCl release)
Claim 6 adds:
- Tablet release limits based on USP Apparatus 2:
- Tablet releases ≤ 29% of opioid/salt after 2 hours using USP Apparatus 2 with 40% ethanolic solution
- Tablet is crushed, then crushed tablets tested 30 min using USP Apparatus 2 with 0.1N hydrochloric acid
- Crushed condition release limit: ≤ 31%
Note: Claim 6 retains the same core/coat/matrix composition architecture as claim 1.
Claim 8 (comparative abuse-release delta in ethanol vs no ethanol)
Claim 8 adds a comparative limitation:
- Includes magnesium stearate in the tablet matrix:
- Mg stearate: 0.25 to 2% by weight of tablet
- Requires a specific “ethanol effect” constraint:
- The percent opioid released after 30 min in 0.1N HCl and 40% ethanol is no more than 21 percentage points greater than the percent released in 0.1N HCl without ethanol
Claim 8 thus targets an abuse scenario emphasizing ethanol-induced extraction or accelerated release.
Claim 9 (hydrocodone-specific independent composition anchor)
Claim 9 specifies the opioid as:
It retains the claim 1 composition architecture and ranges:
- Core: hydrocodone 20-60%, ethylcellulose 10-75%, HPMC 15-50%
- Coat: ethylcellulose 20-60%, glyceryl behenate 10-30%
- Matrix: HPMC 2-20%, lactose 10-75%
What are the quantitative composition ranges that define infringement risk?
Core granule (uncoated granule) ranges (claims 1, 6, 8, 9)
- Opioid (or salt): 20 to 60%
- Ethylcellulose: 10 to 75%
- HPMC: 15 to 50%
Coating composition (coating substantially surrounding the granule)
- Ethylcellulose in coating: 20 to 60%
- Glyceryl behenate: 10 to 30%
Tablet matrix ranges
- HPMC: 2 to 20%
- Lactose: 10 to 75%
- (only in claim 8) Magnesium stearate: 0.25 to 2%
Dependent “narrowing” examples (claims 10 to 14)
These carve out sub-ranges that can matter for design-arounds and for claim chart mapping:
- Claim 10: glyceryl behenate in coating 10 to 20%
- Claim 11: coating amount in coated granule 30 to 60% by weight
- Claim 12: lactose is spray-dried lactose
- Claim 13: tablet-matrix HPMC 2 to 10%
- Claim 14: granule ethylcellulose 40 to 75% and granule HPMC 22 to 50%
What are the abuse-resistant performance tests and numeric limits?
The claims tie abuse resistance to USP Apparatus 2 dissolution testing with explicit media and sample state (intact vs crushed). The performance thresholds define the functional boundary of the protection.
Dependent claim 2 (crushed granule release in dissolution medium)
- Condition: granules are crushed
- Test: USP Apparatus 2, 30 minutes
- Medium: dissolution media (as recited; dependent claims do not repeat the specific medium name here, but other claims do)
- Limit: ≤ 21% opioid released
Dependent claim 4 (more stringent crushed granule release)
- Same crush + apparatus + time framework as claim 2
- Limit: ≤ 15%
Dependent claim 3 (glyceryl behenate vs magnesium stearate comparative performance)
- Condition: crushed coated granules tested 30 min in USP Apparatus 2
- Medium: dissolution media (again not explicitly repeated in the text of claim 3, but the claim references the same general approach as claim 2)
- Comparative limitation:
- Release is lower for glyceryl behenate coating vs similar coated particles with magnesium stearate instead of glyceryl behenate
- Dependent claim 4 then sets a more exact threshold.
Independent-style claim 6 (intact ethanol challenge + crushed acid challenge)
- Intact tablet:
- ≤ 29% release after 2 hours, USP Apparatus 2 with 40% ethanolic solution
- Crush condition:
- After crushing, ≤ 31% release after 30 minutes, USP Apparatus 2 with 0.1N hydrochloric acid
Independent-style claim 8 (ethanol differential requirement)
- Compare two conditions, both at 30 minutes:
- With ethanol: 0.1N HCl + 40% ethanol
- Without ethanol: 0.1N HCl
- Limit:
- Ethanol condition percent released is no more than 21 percentage points greater than the no-ethanol condition
How do the claims treat formulation substitutes and design-arounds?
Glyceryl behenate is the key “substitution blocker”
Claim 3 explicitly compares glyceryl behenate vs magnesium stearate substitution in the coating and ties lower release to the glyceryl behenate embodiment.
This matters because many abuse-resistant formulations attempt to use common hydrophobes/lubricants or wax-like excipients in coating layers. Here, glyceryl behenate is singled out by name in the coating composition ranges and by comparison tests.
Ethanol challenge is used to target extractability
Claims 6 and 8 incorporate ethanol-containing release conditions, which capture abuse scenarios involving alcohol co-ingestion or ethanol-based tampering.
Any design-around must preserve release performance under:
- 40% ethanolic dissolution for intact tablet (claim 6)
- differential ethanol effect between ethanol and no-ethanol conditions (claim 8)
Crush condition is a second axis of protection
The patent requires low opioid release after:
- crushing coated granules (claims 2 and 4)
- crushing tablets under 0.1N HCl (claim 6)
So a formulation that resists intact dissolution but fails crush release can still fall outside the claim scope.
What is the claim “center of gravity” for scope control?
Across claims 1, 6, 8, and 9, the center of gravity is the three-part architecture:
- Core: opioid + ethylcellulose + HPMC (tight quantitative ranges)
- Coating: ethylcellulose + glyceryl behenate (tight quantitative ranges)
- Matrix: HPMC + lactose (with optional Mg stearate and further sub-range limitations)
Then the patent narrows enforceability further through test-based thresholds:
- USP Apparatus 2 release after defined time points
- specific media including 40% ethanol and 0.1N HCl
- crushed vs intact samples
This produces a scope that is at once:
- composition-defined (hard percentage ranges)
- function-defined (hard dissolution release limits under abuse-relevant conditions)
Where does this sit in the broader US abuse-resistant opioid patent landscape?
US abuse-resistant opioid patents typically cluster around:
- multi-layer granule/coat approaches,
- hydrophobic polymer and barrier excipients,
- dissolution-delta criteria under ethanol and/or acidic conditions,
- crush testing frameworks.
This patent fits a pattern where the key differentiation is not only the existence of a coating and rate-controlling polymers, but:
- a specific coating composition (ethylcellulose + glyceryl behenate),
- an HPMC + lactose tablet matrix structure,
- and explicit quantitative abuse metrics (intact ethanol release, crushed acid release, ethanol differential limits).
In enforcement terms, it is positioned to argue that competitors cannot simply swap one lipid or lubricant excipient without changing results enough to breach the numeric release limitations.
What does a practical infringement/clearance screen look like for this patent?
A clearance analysis for freedom-to-operate against US 9,216,176 should map the competitor product to the following elements, in this order:
Element A: granule core composition
Check whether the opioid (or salt) and ethylcellulose and HPMC fall within the stated ranges for the uncoated granule:
- opioid 20-60%
- ethylcellulose 10-75%
- HPMC 15-50%
Element B: coating composition
Check whether the coating substantially surrounding the granule is:
- ethylcellulose 20-60% and
- glyceryl behenate 10-30%
Also check whether the competitor uses a different coating excipient system; claim 3 supports arguments based on the substitution relationship between glyceryl behenate and magnesium stearate.
Element C: matrix composition
Confirm whether tablet matrix includes:
- HPMC 2-20%
- lactose 10-75%
And if Mg stearate is present, whether it lies within 0.25-2% (claim 8 path).
Element D: performance tests
Then map the abuse endpoints:
- Intact tablet release under 40% ethanol (claim 6: ≤29% at 2 hours)
- Crushed release under 0.1N HCl (claim 6: ≤31% at 30 minutes)
- Ethanol differential release (claim 8: ethanol condition no more than 21 percentage points greater)
Finally, test granules directly under USP Apparatus 2 when claims 2/4 are implicated:
- crushed coated granules release ≤21% (claim 2)
- crushed coated granules release ≤15% (claim 4)
Key takeaways
- US 9,216,176 claims an abuse-resistant opioid tablet built from ethylcellulose/HPMC opioid-containing cores coated with ethylcellulose plus glyceryl behenate, embedded in an HPMC/lactose matrix.
- The scope is tightly constrained by granule and coating percentage ranges and by hard quantitative release limits measured in USP Apparatus 2 under abuse-relevant conditions including 40% ethanol and 0.1N HCl, plus crushed sample states.
- The patent’s enforceability leverage is the combination of: specific excipient pairing (glyceryl behenate), specific formulation architecture, and specific dissolution performance endpoints (intact ethanol and crushed acid, plus ethanol differential in claim 8).
FAQs
1) Is glyceryl behenate required to meet the broadest coverage?
Yes. Claim 1’s coating requires glyceryl behenate 10 to 30% (with ethylcellulose 20 to 60%). Dependent claim 3 also frames performance in terms of glyceryl behenate versus magnesium stearate substituted into the coating.
2) Does the patent only cover intact-tablet dissolution?
No. Multiple dependent claims explicitly require crushed testing:
- claim 2 and claim 4: crushed coated granules, USP Apparatus 2, 30 minutes, with release thresholds
- claim 6: crushed tablet, USP Apparatus 2, 30 minutes in 0.1N HCl, with a release threshold
3) Which ethanol-related limitation matters most for claim coverage?
Claim 6 requires ≤29% release after 2 hours in 40% ethanolic solution. Claim 8 adds a differential constraint: ethanol condition release must not exceed the no-ethanol condition by more than 21 percentage points after 30 minutes.
4) Is hydrocodone mandatory for the patent?
No. Claims 1, 6, and 8 are written to cover an opioid and/or salt generally. Claims 5 and 7 specify hydrocodone. Claim 9 is hydrocodone-specific.
5) What formulation component ranges are most likely to drive a design-around?
The tightest “must-match” areas for claim charts are:
- coating: ethylcellulose 20-60% and glyceryl behenate 10-30%
- core: opioid 20-60%, ethylcellulose 10-75%, HPMC 15-50%
- matrix: HPMC 2-20% and lactose 10-75%
Then product-specific compliance must survive the USP Apparatus 2 ethanol and crush release thresholds.
References
[1] US Patent 9,216,176 (claims provided in prompt text).
